Role of Immunophenotyping in Diagnosis, Staging and Targeted therapy of Cutaneous Lymphomas (CTCL and CBCL)

Hernani Cualing, MD
Department of Interdisciplinary Oncology, Pathology and Cell Biology and Hematologic Malignancies, H. Lee Moffitt Cancer Center and Research Institute
CTCL, MF, and Sézary syndrome

• In 1806, mycosis fungoides (MF) was first described¹
  – Alibert, a French dermatologist, described a severe disorder in which large necrotic tumors resembling mushrooms presented on a patient's skin

• In 1979, the term cutaneous T-cell lymphoma (CTCL) was proposed at an international workshop sponsored by the National Cancer Institute and as coined by the Lutzner group in 1975 ²,³
  – CTCL was used to describe a heterogenous group of malignant T-cell lymphomas with primary manifestations in the skin
  – MF is the most common type of CTCL
  – Sézary syndrome (SS) is a variant of MF, occurring in about 5% of all cases of MF

³Lutzner, Edelson et al Cutaneous T cell lymphomas: The Sezary Syndrome, MF and related disorders, Ann Int Med 1975
Epidemiology of MF

- Frequency

- US: approximately 1900 new cases of MF occur per year (ie, 0.64 cases per 100,000 population)*

- The continued rise in CTCL is substantial, and the cause of this increase is unknown
  - More common in men and blacks (2:1 for both)
  - Majority of patients are aged 45–65 years

- Mortality/morbidity

  - The overall mortality rate is 0.064 per 100,000 persons; however, the mortality rate widely varies depending on stage of disease at diagnosis
New WHO-EORTC Classification

• Facilitate more uniformity in diagnosis, management, and treatment of cutaneous lymphomas
• Provides a useful distinction between indolent and more aggressive types of primary cutaneous lymphoma
• This will prevent patients receiving high-grade treatment for low-grade biological disease

### WHO/EORTC Classification of CTCL

<table>
<thead>
<tr>
<th>CTCL, NK-cell Lymphomas</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MF/MF variants and subtypes</strong></td>
</tr>
<tr>
<td>Folliculotropic MF</td>
</tr>
<tr>
<td>Pagetoid reticulosis</td>
</tr>
<tr>
<td>Granulomatous slack skin</td>
</tr>
<tr>
<td><strong>Sézary syndrome</strong></td>
</tr>
<tr>
<td><strong>Adult T-cell leukemia/lymphoma</strong></td>
</tr>
<tr>
<td>Primary cutaneous CD30+ lymphoproliferative disorders</td>
</tr>
<tr>
<td>Primary cutaneous anaplastic large cell lymphoma</td>
</tr>
<tr>
<td>Lymphomatoid papulosis</td>
</tr>
<tr>
<td><strong>Subcutaneous panniculitis-like T-cell lymphoma</strong></td>
</tr>
<tr>
<td><strong>Extranodal NK/T-cell lymphoma, nasal type</strong></td>
</tr>
<tr>
<td><strong>Primary cutaneous peripheral T-cell lymphoma, unspecified</strong></td>
</tr>
<tr>
<td>Primary cutaneous aggressive epidemiotropic CD8+ T-cell lymphoma (provisional)</td>
</tr>
<tr>
<td>Cutaneous gamma/delta T-cell lymphoma (provisional)</td>
</tr>
<tr>
<td>Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma (provisional)</td>
</tr>
</tbody>
</table>

**Precursor Neoplasm- “Blastic NK” or Plasmacytoid Dendritic Hematodermic Neoplasm**

WHO-EORTC CLASSIFICATION OF CUTANEOUS B CELL LYMPHOMA

• **Primary cutaneous B-cell Lymphomas**
  – New WHO-EORTC Classification

• **Indolent**
  – Marginal zone B-cell lymphoma
  – Follicle center lymphoma

• **Intermediate/Aggressive**
  – Diffuse large B-cell lymphoma, leg-type
  – Diffuse large B-cell lymphoma, other

• **Blood**
• **2005;105:**
• **3768-85**
Cutaneous Lymphomas: Making the Diagnosis: Issues

1. Neoplastic vs atypical vs inflammatory
2. B-cell vs T-cell
3. Subtype
4. Primary cutaneous or systemic
Basis: accurate morphology

- Malignant cerebriform cell
  - Good Histology is key to classifying the “atypical cells”
  - Cerebriform morphology shown by thin well stained section of epidermis
Immunophenotyping—Classic MF

- Malignant skin-homing T-cells: $\text{CD45RO}^+$, $\text{CLA}^+_{\text{CLA}} = \text{cutaneous lymphoid antigen.}$
- $\text{CD3}^+$, $\text{CD4}^+$, $\text{CD5}^{+/-}$
- $\text{CD7}^{+/-}$, $\text{CD26}^{+/-}$
- Usually T-cell receptor (TCR) $\alpha\beta^+$
- Cytokine profile may change with disease progression (switch from Th1 to Th2 in advanced disease)
Immunophenotyping

- CD4 and CD8 immunophenotypic can be very useful

Cutaneous T cell infiltrate of small cells

- CD8 > CD4
  - Juxtaepidermal CD8 MF
  - Aggressive CD8 CTCL

- CD4=CD8
  - reactive

- CD4>CD8
  - MF/Sezary Syndrome
Flow Cytometry: Requires fresh tissue

VIRTUAL FLOW CYTOMETRY does not require fresh tissue - formalin fixed tissue is ok

• ROLE IN DIAGNOSIS, STAGING, AND TARGETED THERAPY
**ROLE IN DIAGNOSIS: SKIN BIOPSY MF**

- **Determine markers: Immunopathologic Criteria**
  - 1. CD2, 3 or 5 < 50% of T-cells
  - 2. CD7 < 10% of T-cells
  - 3. Epidermal discordance from expression of CD2,3,5, or 7 on dermal T-cells

- Pimpinelli N, et al. JAAD 2005:
MF and transformation
Diagnostic Criteria: Blood

• In Sézary Syndrome, flow cytometry and molecular evaluation of the blood are needed to establish the diagnosis:

• Demonstration of a T-cell gene rearrangement in the blood and either 1.0 K/µL or more Sézary cells OR one of the 2 criteria outlined by the International Cutaneous Lymphoma Society

  – (1) increased CD4⁺ or CD3⁺ cells with CD4/CD8 of 10 or more by flow cytometry or

  – (2) increase in CD4⁺ cells with an abnormal phenotype ( 40% CD4⁺/CD7⁻ or 30% CD4⁺/CD26)
CAVEATS

- Peripheral blood flow cytometry
  - More objective than “Sézary prep”
  - May indicate abnormality (T cell antigen aberrancy) although
  - Molecular PCR test remain THE definitive test for clonality for T cells
ROLE IN STAGING MF

Table 6. Recommended evaluation/initial staging of the patient with mycosis fungoides/Sézary syndrome

Complete physical examination including

- Determination of type(s) of skin lesions
  - If only patch/plaque disease or erythroderma, then estimate percentage of body surface area involved and note any ulceration of lesions
  - If tumors are present, determine total number of lesions, aggregate volume, largest size lesion, and regions of the body involved

- Identification of any palpable lymph node, especially those ≥ 1.5 cm in largest diameter or firm, irregular, clustered, or fixed
- Identification of any organomegaly

Skin biopsy

- Most indurated area if only one biopsy

- Immunophenotyping to include at least the following markers: CD2, CD3, CD4, CD5, CD7, CD8, and a B-cell marker such as CD20. CD30 may also be indicated in cases where lymphomatoid papulosis, anaplastic lymphoma, or large-cell transformation is considered.

- Evaluation for clonality of TCR gene rearrangement

Blood tests

- CBC with manual differential, liver function tests, LDH, comprehensive chemistries
- TCR gene rearrangement and relatedness to any clone in skin
- Analysis for abnormal lymphocytes by either Sézary cell count with determination absolute number of Sézary cells and/or flow cytometry (including CD4+/CD7- or CD4+/CD25-)

Radiologic tests

- In patients with T1N0B0 stage disease who are otherwise healthy and without complaints directed to a specific organ system, and in selected patients with T2N0B0 disease with limited skin involvement, radiologic studies may be limited to a chest X-ray or ultrasound of the peripheral nodal groups to corroborate absence of adenopathy
- In all patients with other than presumed stage IA disease, or selected patients with limited T3 disease and the absence of adenopathy or blood involvement, CT scans of chest, abdomen, and pelvis alone ± FDG-PET scan are recommended to further evaluate any potential lymphadenopathy, visceral involvement, or abnormal laboratory tests. In patients unable to safely undergo CT scans, MRI may be substituted.

Lymph node biopsy

- Excisional biopsy is indicated in those patients with a node that is either ≥ 1.5 cm in diameter and/or firm, irregular, clustered, or fixed
- Site of biopsy

  - Preference is given to the largest lymph node draining an involved area of the skin or if FDG-PET scan data are available, the node with highest standardized uptake value (SUV).
  - If there is no additional imaging information and multiple nodes are enlarged and otherwise equal in size or consistency, the order of preference is cervical, axillary, and inguinal areas.

- Analysis: pathologic assessment by light microscopy, flow cytometry, and TCR gene rearrangement

• Olsen et al. Revision to the staging and classification.. Blood 2007 1713-1722.
# ROLE IN STAGING NON MF CUTANEOUS LYMPHOMAS

Table 3. ISCL/EORTC recommendations for staging evaluation in cutaneous lymphomas other than MF/SS

<table>
<thead>
<tr>
<th>Complete history/review of systems and physical examination</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Laboratory studies</strong></td>
</tr>
<tr>
<td>Complete blood count, comprehensive serum chemistries, serum LDH</td>
</tr>
<tr>
<td>Whenever indicated, relevant flow cytometric studies of peripheral blood mononuclear cells</td>
</tr>
<tr>
<td><strong>Imaging studies</strong></td>
</tr>
<tr>
<td>CT of chest, abdomen and pelvis with contrast alone or with whole-body PET (18F-FDG); include CT or ultrasound of neck if clinically indicated</td>
</tr>
<tr>
<td>Whole-body integrated PET/CT (as alternative imaging study to the standard contrast-enhanced CT)</td>
</tr>
<tr>
<td><strong>Bone marrow biopsy and aspirate†</strong></td>
</tr>
<tr>
<td>Required in cutaneous lymphomas with intermediate to aggressive clinical behavior as categorized in the WHO-EORTC classification</td>
</tr>
<tr>
<td>Should be considered in cutaneous lymphomas with indolent clinical behavior, but not required unless indicated by other staging assessments</td>
</tr>
<tr>
<td><strong>Additional studies as indicated clinically</strong></td>
</tr>
</tbody>
</table>

*Lymph nodes that are >1.0 cm in short axis and/or have significantly increased PET activity should be sampled for tissue examination (an excisional biopsy is preferable whenever possible).*
ROLE IN THERAPY

• CYTOKINE PROFILE: Decreased cell-mediated immunity with a dominant Th2 cytokine profile is frequently observed in patients with advanced stages of mycosis fungoides or Sézary syndrome.

• TARGETED surface molecules
  – CD52-Alemtuzumab (Campath)
  – (IL-2R alpha chain, CD25 antigen)
  – RITUXAN IN B CELL LYMPHOMAS
Most Important Prognostic Factors

• In multivariate analyses, the most important prognostic factors are related to stage of disease:
  – Presence of visceral disease\(^1,2\)
  – Type of skin involvement\(^1,2\)
  – Lymph node involvement\(^3\)
  – Blood involvement\(^3\)

\(^1\)Bunn PA, Lamberg SI. *Cancer Treatment Reports* 1979;63:725-728
LYMPH NODE GRADING-LN GRADING AIDED BY FLOW CYTOMETRY
FOLLICULAR LYMPHOMA

• Lesional skin
  – Useful in cutaneous lymphomas other than MF (B cell)
    • B cell lymphomas express monotypic light chains
    • Punch Biopsy sensitivity: Flow cytometry detected clonality in 88% (15 of 17) of cutaneous primary or secondary B cell lymphomas, compared to 37% (three of eight) by immunohistochemistry - J Invest Dermatol 121:1522 1530, 2003
Flow cytometry and immunohistochemistry are complementary tools.
FOLLICULAR LYMPHOMA

Bcl-2 or faint+, Mum-1-, CD20+, CD79a+, may show monotypic light chain expression, Bcl-6+; CD10 (+ in follicular, - in diffuse), CD5-.
DLBC, LEG TYPE

- CD20+, CD79a+, monotypic light chain expression
- Bcl-2+ (strong)
- bcl-6+/bcl-6-
- CD10-
- mum-1+
Differential DX: cutaneous lymphoid hyperplasia or cutaneous pseudolymphoma
Cutaneous CD30+ LPD
May be useful in CD30 lymphomas

Represents a biologic and histologic spectrum with lymphomatoid papulosis (a benign disorder with spontaneous regression) at one end and primary cutaneous anaplastic large cell lymphoma (C-ALCL, an indolent CD30+ lymphoma usually treated with local therapy) at the other end.

The classification of CD30+ LPD is predominantly based on the number and size of lesions, number of large CD30+ cells, and the clinical evolution of the lesion (progression versus regression).

It is extremely important to distinguish CALCL from secondary involvement of the skin by systemic ALCL, an aggressive disease that requires multiagent, systemic chemotherapy.
Ki-1+ Anaplastic LCL (ALCL)
Lymphomatoid Papulosis (LyP)
CLA and TRAF-1 are useful in differentiating Lymphomatoid Papulosis, cutaneous ALCL and systemic ALCL.

- LyP
- cutaneous ALCL
- Systemic ALCL

H AND E

TRAF-1

CLA

• H Lee Moffitt Cancer Center and Research Institute, Department Of Pathology and The University of South Florida, College of Medicine
• Dorna Rezania, MD, Elizabeth Sagatys, MD, Marshall E. Kadin, MD, Frank Glass, MD, Hernani Cualing MD.
VIRTUAL FLOW CYTOMETRY OF IMMUNOSTAINED TISSUE IMAGES

**TRAF-1**

LyP

CLA

LyP vs pcALCL (B) (p<0.05)
LyP vs sALCL (C) (p<0.001)

**CLA**

cutaneousALCL

LyP vs sALCL (C) (p<0.001)

Systemic ALCL

LyP (A) vs sALCL (p<0.001), and between pcALCL (B) vs sALCL (p<0.001)
Flow cytometry results may be helpful in differentiating from the similar monocytic leukemia

Summary

- Flow cytometry/immunohistochemistry have important roles in diagnosis, staging and targeted therapy of Cutaneous Lymphomas including MF.
- Non MF peripheral T cell lymphomas and B cell lymphomas of the skin and CD30 lymphomas workup should include immunophenotyping modalities.
- Fresh tissue is amenable to flow cytometry and paraffin embedded tissue may benefit from quantitative tissue virtual flow cytometry.
- Non MF PTCL, CD30 lymphomas and CBCL are unique lymphoproliferative process with clinical course and outcome very different from histopathologically similar nodal lymphomas.
- Cutaneous lymphoproliferative tumors: regard as lymphomas and send fresh tissue enabling use of ancillary tests.